NASDAQ:UTHR United Therapeutics - UTHR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. $259.68 -4.55 (-1.72%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$258.17▼$263.9750-Day Range$258.84▼$280.4352-Week Range$158.38▼$283.09Volume217,993 shsAverage Volume320,837 shsMarket Capitalization$11.84 billionP/E Ratio17.67Dividend YieldN/APrice Target$283.64 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability United Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.58 Rating ScoreUpside/Downside9.2% Upside$283.64 Price TargetShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.51Based on 9 Articles This WeekInsider TradingSelling Shares$59.03 M Sold Last QuarterProj. Earnings Growth13.16%From $16.57 to $18.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.63 out of 5 starsMedical Sector91st out of 1,055 stocksPharmaceutical Preparations Industry31st out of 519 stocks 2.3 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 9 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $283.64, United Therapeutics has a forecasted upside of 9.2% from its current price of $259.68.Amount of Analyst CoverageUnited Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.93% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently decreased by 1.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 2.5 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for United Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows9 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,027,155.00 in company stock.Percentage Held by Insiders12.40% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.63% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 13.16% in the coming year, from $16.57 to $18.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 17.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.62.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 17.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 99.34.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.56. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics (NASDAQ:UTHR) StockUnited Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives $283.64 Average Target Price from BrokeragesJanuary 27, 2023 | americanbankingnews.comMartine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 21, 2023 | finance.yahoo.com10 Best Healthcare Stocks For RecessionJanuary 21, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 Shares of StockJanuary 21, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Short Interest UpdateJanuary 21, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,160.00 in StockJanuary 20, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 6,000 Shares of StockJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 19, 2023 | finance.yahoo.comAfter Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)January 19, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 SharesJanuary 11, 2023 | markets.businessinsider.comAnalyst Ratings for United TherapeuticsJanuary 9, 2023 | finance.yahoo.comLiquidia inks $100M financing agreement amid patent disputeJanuary 6, 2023 | finance.yahoo.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Intrinsic Value Is Potentially 98% Above Its Share PriceJanuary 5, 2023 | finance.yahoo.comIBD Stock Of The Day United Therapeutics Is Braving Competition, And Eyeing Two EntriesJanuary 2, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comThe Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli LillyDecember 21, 2022 | bizjournals.comDurham drugmaker names new CEO at pivotal junctureDecember 16, 2022 | finance.yahoo.comThe Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionXDecember 9, 2022 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 1,010 Shares of StockDecember 6, 2022 | msn.comMorgan Stanley Maintains Overweight Rating for United Therapeutics: Here's What You Need To KnowDecember 5, 2022 | seekingalpha.comUnited Therapeutics draws Sell at Goldman on lack of growth driversDecember 5, 2022 | markets.businessinsider.com6 Analysts Have This to Say About United TherapeuticsDecember 3, 2022 | finance.yahoo.comWhy Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?December 1, 2022 | finance.yahoo.comUnited Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?November 25, 2022 | seekingalpha.comUnited Therapeutics: Stock With Strong Growth And Attractive ValuationNovember 11, 2022 | msn.comUTHR vs. CORT: Which Stock Should Value Investors Buy Now?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Company Calendar Last Earnings11/02/2022Today1/28/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees965Year Founded1996Price Target and Rating Average Stock Price Forecast$283.64 High Stock Price Forecast$375.00 Low Stock Price Forecast$203.00 Forecasted Upside/Downside+9.2%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$14.70 Trailing P/E Ratio17.67 Forward P/E Ratio15.67 P/E Growth1.56Net Income$475.80 million Net Margins38.03% Pretax Margin49.05% Return on Equity16.63% Return on Assets12.95% Debt Debt-to-Equity Ratio0.18 Current Ratio9.68 Quick Ratio9.39 Sales & Book Value Annual Sales$1.69 billion Price / Sales7.02 Cash Flow$11.47 per share Price / Cash Flow22.64 Book Value$87.90 per share Price / Book2.95Miscellaneous Outstanding Shares45,580,000Free Float39,925,000Market Cap$11.84 billion OptionableOptionable Beta0.62 Social Links Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 68)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $3.51MMr. Michael I. Benkowitz (Age 51)Pres & COO Comp: $1.96MMr. James C. Edgemond (Age 55)CFO & Treasurer Comp: $1.42MMr. Paul A. Mahon J.D. (Age 59)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $1.67MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate VP of HRKevin T. GraySr. VP of Strategic Operations & LogisticsMr. Patrick Poisson (Age 55)Exec. VP of Technical Operations Mr. Gil GoldenSr. VP & Chief Medical OfficerDr. Leigh PetersonVP of Product Devel.More ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInsiders & InstitutionsNew York State Teachers Retirement SystemSold 1,931 shares on 1/27/2023Ownership: 0.130%State of Michigan Retirement SystemBought 200 shares on 1/27/2023Ownership: 0.026%Baldwin Brothers LLC MABought 135 shares on 1/27/2023Ownership: 0.000%Dupont Capital Management CorpSold 305 shares on 1/26/2023Ownership: 0.009%Nkcfo LLCBought 100 shares on 1/26/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions UTHR Stock - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price forecast for 2023? 12 brokerages have issued 12 month price objectives for United Therapeutics' stock. Their UTHR share price forecasts range from $203.00 to $375.00. On average, they predict the company's share price to reach $283.64 in the next year. This suggests a possible upside of 9.2% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2023? United Therapeutics' stock was trading at $278.09 at the beginning of the year. Since then, UTHR shares have decreased by 6.6% and is now trading at $259.68. View the best growth stocks for 2023 here. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings results on Wednesday, November, 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, topping the consensus estimate of $3.57 by $1.34. The biotechnology company earned $516 million during the quarter, compared to analysts' expectations of $492.92 million. United Therapeutics had a trailing twelve-month return on equity of 16.63% and a net margin of 38.03%. What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). What is United Therapeutics' stock symbol? United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR." Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.32%), Wedge Capital Management L L P NC (0.31%), Allspring Global Investments Holdings LLC (0.27%), New York State Teachers Retirement System (0.13%), Comerica Bank (0.06%) and Yousif Capital Management LLC (0.05%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is United Therapeutics' stock price today? One share of UTHR stock can currently be purchased for approximately $259.68. How much money does United Therapeutics make? United Therapeutics (NASDAQ:UTHR) has a market capitalization of $11.84 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.70 on an earnings per share basis. How many employees does United Therapeutics have? The company employs 965 workers across the globe. How can I contact United Therapeutics? United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291. This page (NASDAQ:UTHR) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.